{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:36:42Z","timestamp":1792154202809,"version":"4.4.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Women's Health"],"DOI":"10.1186\/s12905-025-03787-z","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T09:31:10Z","timestamp":1749202270000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The safety and efficacy of liraglutide combined with metformin in clinical treatment of polycystic ovary syndrome patients: a meta-analysis"],"prefix":"10.1186","volume":"25","author":[{"given":"Rongmei","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,6]]},"reference":[{"issue":"11","key":"3787_CR1","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.3390\/ijerph15112589","volume":"15","author":"WM Wolf","year":"2018","unstructured":"Wolf WM, Wattick RA, Kinkade ON, et al. Geographical Prevalence of Polycystic Ovary Syndrome as Determined by Region and Race\/Ethnicity. Int J Environ Res Public Health. 2018;15(11):2589.","journal-title":"Int J Environ Res Public Health"},{"issue":"1","key":"3787_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12020-019-02085-7","volume":"67","author":"SA Paschou","year":"2020","unstructured":"Paschou SA, Polyzos SA, Anagnostis P, et al. Nonalcoholic fatty liver disease in women with polycystic ovary syndrome. Endocrine. 2020;67(1):1\u20138.","journal-title":"Endocrine"},{"issue":"1","key":"3787_CR3","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12958-016-0173-x","volume":"14","author":"V De Leo","year":"2016","unstructured":"De Leo V, Musacchio MC, Cappelli V, et al. Genetic, hormonal and metabolic aspects of PCOS: an update. Reprod Biol Endocrinol. 2016;14(1):38.","journal-title":"Reprod Biol Endocrinol"},{"issue":"1","key":"3787_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/GRF.0000000000000563","volume":"64","author":"JA Lentscher","year":"2021","unstructured":"Lentscher JA, Decherney AH. Clinical presentation and diagnosis of polycystic ovarian syndrome. Clin Obstet Gynecol. 2021;64(1):3\u201311.","journal-title":"Clin Obstet Gynecol"},{"issue":"8","key":"3787_CR5","doi-asserted-by":"publisher","first-page":"e2695","DOI":"10.1210\/clinem\/dgaa285","volume":"105","author":"H Cena","year":"2020","unstructured":"Cena H, Chiovato L, Nappi RE. Obesity, Polycystic Ovary Syndrome, and Infertility: A New Avenue for GLP-1 Receptor Agonists. J Clin Endocrinol Metab. 2020;105(8):e2695\u2013709.","journal-title":"J Clin Endocrinol Metab"},{"key":"3787_CR6","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jclinepi.2019.03.014","volume":"113","author":"WL Bennett","year":"2019","unstructured":"Bennett WL, Aschmann HE, Puhan MA, et al. A benefit-harm analysis of adding basal insulin vs. sulfonylurea to metformin to manage type II diabetes mellitus in people with multiple chronic conditions. J Clin Epidemiol. 2019;113:92\u2013100.","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"3787_CR7","first-page":"106","volume":"94","author":"T Williams","year":"2016","unstructured":"Williams T, Mortada R, Porter S. Diagnosis and treatment of polycystic ovary syndrome. Am Fam Physician. 2016;94(2):106\u201313.","journal-title":"Am Fam Physician"},{"issue":"2","key":"3787_CR8","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1530\/EJE-09-0733","volume":"162","author":"E Diamanti-Kandarakis","year":"2010","unstructured":"Diamanti-Kandarakis E, Christakou CD, Kandaraki E, et al. Metformin: an old medication of new fashion: evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome. Eur J Endocrinol. 2010;162(2):193\u2013212.","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"3787_CR9","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/s41574-018-0016-2","volume":"14","author":"A Andersen","year":"2018","unstructured":"Andersen A, Lund A, Knop FK, et al. Glucagon-like peptide 1 in health and disease. Nat Rev Endocrinol. 2018;14(7):390\u2013403.","journal-title":"Nat Rev Endocrinol"},{"key":"3787_CR10","doi-asserted-by":"publisher","first-page":"1905108415","DOI":"10.1177\/2042018820938305","volume":"11","author":"MA Abdalla","year":"2020","unstructured":"Abdalla MA, Deshmukh H, Atkin S, et al. A review of therapeutic options for managing the metabolic aspects of polycystic ovary syndrome. Ther Adv Endocrinol Metab. 2020;11:1905108415.","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"9","key":"3787_CR11","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1093\/humrep\/deg367","volume":"18","author":"PG Crosignani","year":"2003","unstructured":"Crosignani PG, Colombo M, Vegetti W, et al. Overweight and obese anovulatory patients with polycystic ovaries: parallel improvements in anthropometric indices, ovarian physiology and fertility rate induced by diet. Hum Reprod. 2003;18(9):1928\u201332.","journal-title":"Hum Reprod"},{"key":"3787_CR12","doi-asserted-by":"publisher","first-page":"945609","DOI":"10.3389\/fendo.2022.945609","volume":"13","author":"C Xing","year":"2022","unstructured":"Xing C, Zhao H, Zhang J, et al. Effect of metformin versus metformin plus liraglutide on gonadal and metabolic profiles in overweight patients with polycystic ovary syndrome. Front Endocrinol (Lausanne). 2022;13:945609.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"3787_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1530\/EJE-18-0175","volume":"179","author":"V Salamun","year":"2018","unstructured":"Salamun V, Jensterle M, Janez A, et al. Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: a pilot randomized study. Eur J Endocrinol. 2018;179(1):1\u201311.","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"3787_CR14","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.","journal-title":"PLoS Med"},{"issue":"8","key":"3787_CR15","first-page":"5","volume":"36","author":"Hu Sun Haiyun","year":"2021","unstructured":"Sun Haiyun Hu, Shuifang YX. Effect of liraglutide combined with metformin on ovarian dysfunction of women with polycystic ovary syndrome. Drugs Clin. 2021;36(8):5.","journal-title":"Drugs Clin"},{"key":"3787_CR16","first-page":"5","volume":"7","author":"H Zhaosui","year":"2015","unstructured":"Zhaosui H, Lili L, Jiao Y, et al. Efficacy of liraglutide on metabolic parameters and pregnancy in polycystic ovary syndrome patients combined with impaired glucose tolerance and obesity. Chin J Diabetes Mellitus. 2015;7:5.","journal-title":"Chin J Diabetes Mellitus"},{"key":"3787_CR17","unstructured":"Liang S. Efficacy of liraglutide in adjuvant treatment of polycystic ovary syndrome. Electron J Pract Gynecol Endocrinol. 2021(31)."},{"key":"3787_CR18","unstructured":"Li Y, Deng H, Tan C, et al. Efficacy of liraglutide in adjuvant treatment of polycystic ovary syndrome and its effect on ovarian function. J Med Theor Prac. 2022(035\u2013010)."},{"issue":"32","key":"3787_CR19","first-page":"151","volume":"21","author":"H Li","year":"2023","unstructured":"Li H. Therapeutic effect of liraglutide combined with metformin for infertile patients with polycystic ovary syndrome. Chin Foreign Med Res. 2023;21(32):151\u20135.","journal-title":"Chin Foreign Med Res"},{"key":"3787_CR20","first-page":"14","volume":"009","author":"T Mingdeng","year":"2022","unstructured":"Mingdeng T, Xiaoping C, Ping C. Effects of liraglutide combined with metformin on glucose and lipid metabolism and reproductive function in patients with obese polycystic ovary syndrome. Chin J Fam Plann Gynecotokology. 2022;009:14.","journal-title":"Chin J Fam Plann Gynecotokology"},{"key":"3787_CR21","first-page":"26","volume":"032","author":"Z Bo","year":"2019","unstructured":"Bo Z. Clinical effect of Lilalutide combined with Metformin Hydrochloride in the treatment of polycystic ovary syndrome with glycolipid metabolism disorder. China Modern Med. 2019;032:26.","journal-title":"China Modern Med"},{"issue":"1","key":"3787_CR22","first-page":"8","volume":"23","author":"Lu Hao Jianmin","year":"2020","unstructured":"Hao Jianmin Lu, Tao QJ, et al. Effect of liraglutide on the clinical pregnancy rate of obese infertile women with polycystic ovary syndrome. Pract Pharm Clin Remedies. 2020;23(1):8.","journal-title":"Pract Pharm Clin Remedies"},{"issue":"12","key":"3787_CR23","first-page":"4","volume":"36","author":"Y Qian","year":"2021","unstructured":"Qian Y, Haixiong Z, Xuemei H, et al. Effect of liraglutide on fertility function in obese patients with PCOS. J North Sichuan Med Coll. 2021;36(12):4.","journal-title":"J North Sichuan Med Coll"},{"issue":"3","key":"3787_CR24","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1530\/EJE-13-0797","volume":"170","author":"M Jensterle Sever","year":"2014","unstructured":"Jensterle Sever M, Kocjan T, Pfeifer M, et al. Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin. Eur J Endocrinol. 2014;170(3):451\u20139.","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"3787_CR25","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.cnur.2018.04.008","volume":"53","author":"RK Meier","year":"2018","unstructured":"Meier RK. Polycystic Ovary Syndrome. Nurs Clin North Am. 2018;53(3):407\u201320.","journal-title":"Nurs Clin North Am"},{"issue":"4","key":"3787_CR26","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/nrendo.2010.217","volume":"7","author":"MO Goodarzi","year":"2011","unstructured":"Goodarzi MO, Dumesic DA, Chazenbalk G, et al. Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nat Rev Endocrinol. 2011;7(4):219\u201331.","journal-title":"Nat Rev Endocrinol"},{"issue":"2","key":"3787_CR27","doi-asserted-by":"publisher","first-page":"122","DOI":"10.3109\/03014460.2012.655776","volume":"39","author":"L Nasreddine","year":"2012","unstructured":"Nasreddine L, Naja F, Tabet M, et al. Obesity is associated with insulin resistance and components of the metabolic syndrome in Lebanese adolescents. Ann Hum Biol. 2012;39(2):122\u20138.","journal-title":"Ann Hum Biol"},{"issue":"5","key":"3787_CR28","doi-asserted-by":"publisher","first-page":"e126119","DOI":"10.1371\/journal.pone.0126119","volume":"10","author":"V Hoang","year":"2015","unstructured":"Hoang V, Bi J, Mohankumar SM, et al. Liraglutide improves hypertension and metabolic perturbation in a rat model of polycystic ovarian syndrome. PLoS One. 2015;10(5):e126119.","journal-title":"PLoS One"},{"issue":"7","key":"3787_CR29","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1007\/s43032-024-01503-0","volume":"31","author":"S Ji","year":"2024","unstructured":"Ji S, Yang H, Ji Y, et al. Liraglutide improves PCOS symptoms in rats by targeting FDX1. Reprod Sci. 2024;31(7):2049\u201358.","journal-title":"Reprod Sci"},{"key":"3787_CR30","doi-asserted-by":"publisher","first-page":"170624","DOI":"10.1016\/j.peptides.2021.170624","volume":"145","author":"LM Wu","year":"2021","unstructured":"Wu LM, Wang YX, Zhan Y, et al. Dulaglutide, a long-acting GLP-1 receptor agonist, can improve hyperandrogenemia and ovarian function in DHEA-induced PCOS rats. Peptides. 2021;145:170624.","journal-title":"Peptides"},{"issue":"2","key":"3787_CR31","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/jdi.12888","volume":"10","author":"WH Feng","year":"2019","unstructured":"Feng WH, Bi Y, Li P, et al. Effects of liraglutide, metformin and gliclazide on body composition in patients with both type 2 diabetes and non-alcoholic fatty liver disease: a randomized trial. J Diabetes Investig. 2019;10(2):399\u2013407.","journal-title":"J Diabetes Investig"},{"issue":"8","key":"3787_CR32","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1111\/1753-0407.12555","volume":"9","author":"W Feng","year":"2017","unstructured":"Feng W, Gao C, Bi Y, et al. Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non-alcoholic fatty liver disease. J Diabetes. 2017;9(8):800\u20139.","journal-title":"J Diabetes"},{"key":"3787_CR33","doi-asserted-by":"publisher","first-page":"108487","DOI":"10.1016\/j.diabres.2020.108487","volume":"170","author":"W Guo","year":"2020","unstructured":"Guo W, Tian W, Lin L, et al. Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: a randomized placebo-controlled trial. Diabetes Res Clin Pract. 2020;170:108487.","journal-title":"Diabetes Res Clin Pract"},{"issue":"5","key":"3787_CR34","doi-asserted-by":"publisher","first-page":"e3292","DOI":"10.1002\/dmrr.3292","volume":"36","author":"L Liu","year":"2020","unstructured":"Liu L, Yan H, Xia M, et al. Efficacy of exenatide and insulin glargine on nonalcoholic fatty liver disease in patients with type 2 diabetes. Diabetes Metab Res Rev. 2020;36(5):e3292.","journal-title":"Diabetes Metab Res Rev"},{"issue":"3","key":"3787_CR35","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1017\/S1368980015001585","volume":"19","author":"R Burrows","year":"2016","unstructured":"Burrows R, Correa-Burrows P, Reyes M, et al. High cardiometabolic risk in healthy Chilean adolescents: associations with anthropometric, biological and lifestyle factors. Public Health Nutr. 2016;19(3):486\u201393.","journal-title":"Public Health Nutr"},{"issue":"7","key":"3787_CR36","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1210\/jc.2006-2725","volume":"92","author":"E Carmina","year":"2007","unstructured":"Carmina E, Bucchieri S, Esposito A, et al. Abdominal fat quantity and distribution in women with polycystic ovary syndrome and extent of its relation to insulin resistance. J Clin Endocrinol Metab. 2007;92(7):2500\u20135.","journal-title":"J Clin Endocrinol Metab"},{"key":"3787_CR37","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3389\/fendo.2019.00155","volume":"10","author":"LB Knudsen","year":"2019","unstructured":"Knudsen LB, Lau J. The Discovery and Development of Liraglutide and Semaglutide. Front Endocrinol (Lausanne). 2019;10:155.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"3787_CR38","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s12958-015-0134-9","volume":"13","author":"A Dumont","year":"2015","unstructured":"Dumont A, Robin G, Catteau-Jonard S, et al. Role of Anti-M\u00fcllerian Hormone in pathophysiology, diagnosis and treatment of Polycystic Ovary Syndrome: a review. Reprod Biol Endocrinol. 2015;13:137.","journal-title":"Reprod Biol Endocrinol"},{"key":"3787_CR39","doi-asserted-by":"publisher","first-page":"1294406","DOI":"10.3389\/fendo.2023.1294406","volume":"14","author":"S Malik","year":"2023","unstructured":"Malik S, Saeed S, Saleem A, et al. Alternative treatment of polycystic ovary syndrome: pre-clinical and clinical basis for using plant-based drugs. Front Endocrinol (Lausanne). 2023;14:1294406.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"10","key":"3787_CR40","doi-asserted-by":"publisher","first-page":"799","DOI":"10.3109\/09513590.2016.1169267","volume":"32","author":"S Bhandari","year":"2016","unstructured":"Bhandari S, Ganguly I, Bhandari M, et al. Effect of sleeve gastrectomy bariatric surgery-induced weight loss on serum AMH levels in reproductive aged women. Gynecol Endocrinol. 2016;32(10):799\u2013802.","journal-title":"Gynecol Endocrinol"},{"issue":"6","key":"3787_CR41","doi-asserted-by":"publisher","first-page":"e12559","DOI":"10.1111\/cob.12559","volume":"12","author":"J Kloos","year":"2022","unstructured":"Kloos J, Coyne K, Weinerman R. The relationship between anti-M\u00fcllerian hormone, body mass index and weight loss: a review of the literature. Clin Obes. 2022;12(6):e12559.","journal-title":"Clin Obes"},{"issue":"1","key":"3787_CR42","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.rbmo.2016.04.007","volume":"33","author":"D Garg","year":"2016","unstructured":"Garg D, Tal R. The role of AMH in the pathophysiology of polycystic ovarian syndrome. Reprod Biomed Online. 2016;33(1):15\u201328.","journal-title":"Reprod Biomed Online"},{"issue":"4","key":"3787_CR43","doi-asserted-by":"publisher","first-page":"P1","DOI":"10.1530\/EJE-14-0253","volume":"171","author":"G Conway","year":"2014","unstructured":"Conway G, Dewailly D, Diamanti-Kandarakis E, et al. The polycystic ovary syndrome: a position statement from the European Society of Endocrinology. Eur J Endocrinol. 2014;171(4):P1\u201329.","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"3787_CR44","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s00404-015-3976-7","volume":"293","author":"M Niafar","year":"2016","unstructured":"Niafar M, Pourafkari L, Porhomayon J, et al. A systematic review of GLP-1 agonists on the metabolic syndrome in women with polycystic ovaries. Arch Gynecol Obstet. 2016;293(3):509\u201315.","journal-title":"Arch Gynecol Obstet"},{"issue":"1","key":"3787_CR45","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/dom.13053","volume":"20","author":"S Fr\u00f8ssing","year":"2018","unstructured":"Fr\u00f8ssing S, Nylander M, Chabanova E, et al. Effect of liraglutide on ectopic fat in polycystic ovary syndrome: a randomized clinical trial. Diabetes Obes Metab. 2018;20(1):215\u20138.","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"3787_CR46","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1089\/met.2017.0095","volume":"15","author":"S Ferjan","year":"2017","unstructured":"Ferjan S, Janez A, Jensterle M. Dipeptidyl Peptidase-4 inhibitor sitagliptin prevented weight regain in obese women with polycystic ovary syndrome previously treated with liraglutide: a pilot randomized study. Metab Syndr Relat Disord. 2017;15(10):515\u201320.","journal-title":"Metab Syndr Relat Disord"},{"issue":"1","key":"3787_CR47","doi-asserted-by":"publisher","first-page":"69","DOI":"10.4158\/EP-2017-0027","volume":"24","author":"S Ferjan","year":"2018","unstructured":"Ferjan S, Janez A, Jensterle M. DPP4 inhibitor sitagliptin as a potential treatment option in metformin-intolerant obese women with polycystic ovary syndrome: a pilot randomized study. Endocr Pract. 2018;24(1):69\u201377.","journal-title":"Endocr Pract"},{"issue":"7","key":"3787_CR48","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1210\/jc.2008-0115","volume":"93","author":"K Elkind-Hirsch","year":"2008","unstructured":"Elkind-Hirsch K, Marrioneaux O, Bhushan M, et al. Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2008;93(7):2670\u20138.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"3787_CR49","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.ncrna.2024.01.002","volume":"9","author":"R Heidarzadehpilehrood","year":"2024","unstructured":"Heidarzadehpilehrood R, Pirhoushiaran M. Biomarker potential of competing endogenous RNA networks in Polycystic Ovary Syndrome (PCOS). Noncoding RNA Res. 2024;9(2):624\u201340.","journal-title":"Noncoding RNA Res"},{"issue":"3","key":"3787_CR50","doi-asserted-by":"publisher","first-page":"103129","DOI":"10.1016\/j.arcmed.2024.103129","volume":"56","author":"R Heidarzadehpilehrood","year":"2024","unstructured":"Heidarzadehpilehrood R, Pirhoushiaran M, Osman MB, et al. A high-throughput RNA sequency of peripheral blood mononuclear cells reveals on inflammatory state in women with PCOS. Arch Med Res. 2024;56(3):103129.","journal-title":"Arch Med Res"},{"key":"3787_CR51","doi-asserted-by":"publisher","first-page":"100343","DOI":"10.1016\/j.metop.2024.100343","volume":"25","author":"R Heidarzadehpilehrood","year":"2025","unstructured":"Heidarzadehpilehrood R, Hamid HA, Pirhoushiaran M. Vitamin D receptor (VDR) gene polymorphisms and risk for polycystic ovary syndrome and infertility: an updated systematic review and meta-analysis. Metabol Open. 2025;25:100343.","journal-title":"Metabol Open"}],"container-title":["BMC Women's Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-025-03787-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12905-025-03787-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-025-03787-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T11:03:35Z","timestamp":1749207815000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcwomenshealth.biomedcentral.com\/articles\/10.1186\/s12905-025-03787-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,6]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3787"],"URL":"https:\/\/doi.org\/10.1186\/s12905-025-03787-z","relation":{},"ISSN":["1472-6874"],"issn-type":[{"value":"1472-6874","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,6]]},"assertion":[{"value":"31 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"282"}}